Stock Track | CVS Health Soars 5.33% in Pre-market on Strong Q2 Earnings Beat, Raised Guidance, and GLP-1 Strategy Expansion

Stock Track

Aug 05

CVS Health shares surged 5.33% in pre-market trading after the company reported quarterly results that significantly exceeded analyst expectations and lifted its full-year outlook.

The healthcare giant posted second-quarter revenue of $106.1 billion, handily beating the consensus estimate of $100.1 billion. Adjusted earnings per share came in at $2.58, far above the $1.85 Wall Street had projected. The company's medical benefit ratio improved to 87.4%, notably better than the 90.03% estimate, indicating stronger cost management.

CVS also raised its full-year adjusted EPS guidance to a range of $7.90 to $8.10, surpassing the $7.45 consensus. Investors welcomed the upgraded forecast alongside strategic announcements, including a collaboration with Eli Lilly to provide transparent pricing for Zepbound and Foundayo patients, and an expansion of its direct-to-consumer weight management offerings with $29 MinuteClinic virtual visits for GLP-1 medications. These moves reinforced confidence in the company's growth trajectory and competitive positioning in the healthcare services market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1152397773"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152397773\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152397773?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-05 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152397773","market":"nz","top_or_hot":-1,"title":"Stock Track | CVS Health Soars 5.33% in Pre-market on Strong Q2 Earnings Beat, Raised Guidance, and GLP-1 Strategy Expansion","media":"Stock Track","content":"<p>CVS Health shares surged 5.33% in pre-market trading after the company reported quarterly results that significantly exceeded analyst expectations and lifted its full-year outlook.</p>\n<p>The healthcare giant posted second-quarter revenue of $106.1 billion, handily beating the consensus estimate of $100.1 billion. Adjusted earnings per share came in at $2.58, far above the $1.85 Wall Street had projected. The company's medical benefit ratio improved to 87.4%, notably better than the 90.03% estimate, indicating stronger cost management.</p>\n<p>CVS also raised its full-year adjusted EPS guidance to a range of $7.90 to $8.10, surpassing the $7.45 consensus. Investors welcomed the upgraded forecast alongside strategic announcements, including a collaboration with Eli Lilly to provide transparent pricing for Zepbound and Foundayo patients, and an expansion of its direct-to-consumer weight management offerings with $29 MinuteClinic virtual visits for GLP-1 medications. These moves reinforced confidence in the company's growth trajectory and competitive positioning in the healthcare services market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CVS Health Soars 5.33% in Pre-market on Strong Q2 Earnings Beat, Raised Guidance, and GLP-1 Strategy Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CVS Health Soars 5.33% in Pre-market on Strong Q2 Earnings Beat, Raised Guidance, and GLP-1 Strategy Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-05 18:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CVS Health shares surged 5.33% in pre-market trading after the company reported quarterly results that significantly exceeded analyst expectations and lifted its full-year outlook.</p>\n<p>The healthcare giant posted second-quarter revenue of $106.1 billion, handily beating the consensus estimate of $100.1 billion. Adjusted earnings per share came in at $2.58, far above the $1.85 Wall Street had projected. The company's medical benefit ratio improved to 87.4%, notably better than the 90.03% estimate, indicating stronger cost management.</p>\n<p>CVS also raised its full-year adjusted EPS guidance to a range of $7.90 to $8.10, surpassing the $7.45 consensus. Investors welcomed the upgraded forecast alongside strategic announcements, including a collaboration with Eli Lilly to provide transparent pricing for Zepbound and Foundayo patients, and an expansion of its direct-to-consumer weight management offerings with $29 MinuteClinic virtual visits for GLP-1 medications. These moves reinforced confidence in the company's growth trajectory and competitive positioning in the healthcare services market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVS","symbol_name":"西维斯健康","start_time":0,"source_url":"","article_id":"1152397773","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152397773","pubTimestamp":1785926112,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CVS Health shares surged 5.33% in pre-market trading after the company reported quarterly results that significantly exceeded analyst expectations and lifted its full-year outlook. The healthcare...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVS":"西维斯健康"},"translate_title":"股票跟踪 | 由于第二季度盈利强劲、指引上调和 GLP-1 策略扩张，CVS Health 盘前飙升 5.33%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVS":1},"content_text":"CVS Health shares surged 5.33% in pre-market trading after the company reported quarterly results that significantly exceeded analyst expectations and lifted its full-year outlook.\nThe healthcare giant posted second-quarter revenue of $106.1 billion, handily beating the consensus estimate of $100.1 billion. Adjusted earnings per share came in at $2.58, far above the $1.85 Wall Street had projected. The company's medical benefit ratio improved to 87.4%, notably better than the 90.03% estimate, indicating stronger cost management.\nCVS also raised its full-year adjusted EPS guidance to a range of $7.90 to $8.10, surpassing the $7.45 consensus. Investors welcomed the upgraded forecast alongside strategic announcements, including a collaboration with Eli Lilly to provide transparent pricing for Zepbound and Foundayo patients, and an expansion of its direct-to-consumer weight management offerings with $29 MinuteClinic virtual visits for GLP-1 medications. These moves reinforced confidence in the company's growth trajectory and competitive positioning in the healthcare services market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}